CN109432073A - Mgbg在制备治疗或预防进行性ms及其进展的药物中的用途 - Google Patents

Mgbg在制备治疗或预防进行性ms及其进展的药物中的用途 Download PDF

Info

Publication number
CN109432073A
CN109432073A CN201811424556.8A CN201811424556A CN109432073A CN 109432073 A CN109432073 A CN 109432073A CN 201811424556 A CN201811424556 A CN 201811424556A CN 109432073 A CN109432073 A CN 109432073A
Authority
CN
China
Prior art keywords
purposes
group
mgbg
certain embodiments
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201811424556.8A
Other languages
English (en)
Chinese (zh)
Inventor
J·布利策
J·麦基尔恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pathologica LLC
Original Assignee
Pathologica LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pathologica LLC filed Critical Pathologica LLC
Publication of CN109432073A publication Critical patent/CN109432073A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN201811424556.8A 2013-01-08 2014-01-08 Mgbg在制备治疗或预防进行性ms及其进展的药物中的用途 Pending CN109432073A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361750336P 2013-01-08 2013-01-08
US61/750,336 2013-01-08
US201361823276P 2013-05-14 2013-05-14
US61/823,276 2013-05-14
CN201480007129.3A CN105163730B (zh) 2013-01-08 2014-01-08 用于治疗脱髓鞘疾病的方法和组合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480007129.3A Division CN105163730B (zh) 2013-01-08 2014-01-08 用于治疗脱髓鞘疾病的方法和组合物

Publications (1)

Publication Number Publication Date
CN109432073A true CN109432073A (zh) 2019-03-08

Family

ID=51167347

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201811424556.8A Pending CN109432073A (zh) 2013-01-08 2014-01-08 Mgbg在制备治疗或预防进行性ms及其进展的药物中的用途
CN201480007129.3A Expired - Fee Related CN105163730B (zh) 2013-01-08 2014-01-08 用于治疗脱髓鞘疾病的方法和组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201480007129.3A Expired - Fee Related CN105163730B (zh) 2013-01-08 2014-01-08 用于治疗脱髓鞘疾病的方法和组合物

Country Status (11)

Country Link
US (2) US10085955B2 (enExample)
EP (2) EP2943189B1 (enExample)
JP (2) JP6370804B2 (enExample)
CN (2) CN109432073A (enExample)
AU (2) AU2014205529B2 (enExample)
BR (1) BR112015016189A8 (enExample)
CA (1) CA2896977C (enExample)
DK (1) DK2943189T3 (enExample)
ES (1) ES2859553T3 (enExample)
IL (1) IL239851B (enExample)
WO (1) WO2014110154A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2121586B1 (en) 2007-03-09 2017-03-08 Pathologica LLC Mgbg for the regulation of osteopontin and the treatment of multiple sclerosis
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
WO2011009039A2 (en) 2009-07-16 2011-01-20 Pathologica Llc Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
NO2665471T3 (enExample) 2011-01-19 2018-05-26
BR112015016189A8 (pt) 2013-01-08 2019-10-22 Pathologica Llc usos de metilglioxal bis (guanilhidrazona) (“mgbg”), uso de metilglioxal bis (guanilhidrazona) (“mgbg”) e um agente e composição farmacêutica
US20160058730A1 (en) * 2014-08-29 2016-03-03 Cadila Healthcare Limited Pharmaceutical compositions of teriflunomide
MA41785A (fr) 2015-03-20 2018-01-23 Biogen Ma Inc Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques
EP3118621A1 (en) * 2015-07-14 2017-01-18 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Methods and compositions for the diagnosis and for the treatment of adrenoleukodystrophy
WO2017042274A1 (en) * 2015-09-08 2017-03-16 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Quinoline derivates for use in treating leukodystrophy and treatment method
CN108883077A (zh) * 2016-03-07 2018-11-23 国立大学法人大阪大学 神经损伤治疗用药剂缓释片材
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
SMT202500136T1 (it) 2016-08-31 2025-05-12 Mapi Pharma Ltd Sistemi a deposito comprendenti glatiramer acetato
US11167003B2 (en) 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems
AU2019253059A1 (en) * 2018-04-13 2020-11-12 Mordechai Chevion Compositions and methods for treatment of demyelination
EP4094765A1 (en) * 2019-12-19 2022-11-30 Active Biotech AB Compounds for treatment of eye diseases associated with excessive vascularisation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010045265A1 (en) * 2008-10-13 2010-04-22 Biovista, Inc. Compositions and methods for treating multiple sclerosis
CN102686222A (zh) * 2009-07-16 2012-09-19 帕萨罗杰卡有限公司 包含mgbg的口服递送药物以及治疗疾病的方法
CN102770142A (zh) * 2010-01-04 2012-11-07 神经科技制药有限公司 二氮嗪在治疗或预防中枢神经系统自体免疫脱髓鞘疾病中的应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4201788A (en) 1976-10-20 1980-05-06 University Patents, Inc. Process for alleviating proliferative skin diseases
US5614557A (en) 1977-07-11 1997-03-25 Marion Merrell Et Compagnie C/O Merrell Pharmaceuticals Inc. Method of controlling tumor growth rate
US4520031A (en) 1981-06-01 1985-05-28 The United States Of America As Represented By The Secretary Of Department Of Health And Human Services Method for reducing toxic effects of methyl-glyoxal bis-guanylhydrazone
US5639600A (en) 1994-08-05 1997-06-17 The Regents Of The University Of California Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement
US5580715A (en) 1994-08-05 1996-12-03 The Regents Of The University Of California Diagnosis of cancer having clonal macrophage involvement
US5698563A (en) 1995-01-13 1997-12-16 Alteon Inc. Bis- hydrazones!
ATE294583T1 (de) 1996-09-13 2005-05-15 Univ Florida Verfahren zur hemmung von eif5a-biosynthese
AR009380A1 (es) 1996-10-21 2000-04-12 Sumitomo Chemical Co Proceso de preparacion de un derivado de piridazin-3-ona, util como herbicida, acido carboxilico de utilizacion en el mismo, sal de este ultimo y proceso para preparar dicho acido carboxilico
US6083496A (en) 1996-10-22 2000-07-04 Universite Laval Polyamine transport inhibitors
WO1999003823A2 (en) 1997-07-15 1999-01-28 Oridigm Corporation Novel polyamine analogues as therapeutic and diagnostic agents
US5889061A (en) 1997-10-15 1999-03-30 Wisconsin Alumni Research Foundation Conformationally restricted polyamines
US8198334B2 (en) 1997-10-27 2012-06-12 Pathologica Llc Methods for modulating macrophage proliferation in ocular disease using polyamine analogs
US7087648B1 (en) 1997-10-27 2006-08-08 The Regents Of The University Of California Methods for modulating macrophage proliferation using polyamine analogs
US6169115B1 (en) 1998-05-22 2001-01-02 Rima Kaddurah-Daouk Use of aminoguanidine analogs for the treatment of diseases of the nervous system
EP1177197B1 (en) 1999-04-30 2006-08-09 Cellgate, Inc. Polyamines and their use in therapy
WO2002038105A2 (en) 2000-11-08 2002-05-16 Slil Biomedical Corporation Novel polyamine analog-amino acid conjugates useful as anticancer agents
US6544541B1 (en) * 1999-06-02 2003-04-08 Cardiovascular Solutions, Inc. Devices and compounds for treating arterial restenosis
CA2400374A1 (en) * 2000-02-18 2001-08-23 Adrian Gilbert Oral, nasal and pulmonary dosage formualtions of copolymer 1
US7754765B2 (en) 2000-12-01 2010-07-13 Radical Vision Therapeutics Inc Copper chelators for treating ocular inflammation
RU2003124640A (ru) 2001-01-08 2005-02-27 Медиквест Терапевтикс, Инк. (Us) Гидрофобные полиаминные аналоги и способы их применения
CA2456034A1 (en) 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Sustained-release medicines
US7045550B2 (en) 2001-08-07 2006-05-16 Wisconsin Alumni Research Foundation Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy
WO2003016491A2 (en) 2001-08-15 2003-02-27 The Regents Of The University Of California Retrovirus isolated from mantle histiocytes in mantle cell lymphoma
US7211602B2 (en) * 2001-11-16 2007-05-01 Als Therapy Development Foundation, Inc. Treatment of neurodegenerative disorders through the modulation of the polyamine pathway
JP2005519033A (ja) * 2001-11-21 2005-06-30 ザ ボード オブ トラスティーズ オブ レランド スタンフォード ジュニア ユニバーシティ オステオポンチン関連組成物および方法
US7622117B2 (en) 2002-04-17 2009-11-24 Dynamis Therapeutics, Inc. 3-deoxyglucosone and skin
EP1389480A1 (en) * 2002-08-14 2004-02-18 Mondobiotech Interferon SA Therapeutical use of guanylhydrazones for the inhibition of CD83 dependent processes and dendritic cell maturation
EP1613263A4 (en) 2003-01-31 2007-11-28 Pathologica Llc MONITORING AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS
GB2400318B (en) * 2003-04-08 2005-08-10 Novartis Ag Pharmaceutical composition comprising an S1P receptor agonist
US20050042277A1 (en) 2003-07-17 2005-02-24 Irukulla Srinivas Pharmaceutical compositions having a swellable coating
US20050025825A1 (en) 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
US20050113455A1 (en) 2003-10-22 2005-05-26 Bergeron Raymond J.Jr. Method and composition for amelioration of pain
AU2004319105A1 (en) 2004-03-29 2005-11-10 Mediquest Therapeutics, Inc. Polyamine analogs that activate antizyme frameshifting
US7445794B1 (en) 2004-04-29 2008-11-04 The Regents Of The University Of Colorado Methods for treating human proliferative diseases, with a combination of fatty acid metabolism inhibitors and glycolytic inhibitors
US20060189546A1 (en) 2005-01-28 2006-08-24 Ajami Alfred M Compounds for treating autoimmune and demyelinating diseases
US8912214B2 (en) 2005-07-29 2014-12-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of Chk2 kinase inhibitors for cancer treatment
PL1916995T5 (pl) 2005-07-29 2022-10-31 Stichting Groningen Centre For Drug Research Kontrolowany wartością ph impulsowy układ podawczy, sposoby przygotowania i zastosowanie
EP1937235B1 (en) 2005-09-23 2015-07-01 Pathologica, LLC. Methods for treating viral infections using polyamine analogs
WO2007040535A1 (en) 2005-10-03 2007-04-12 Cellgate, Inc. Use of polyamine analogs for treatment and prevention of intestinal polyps
US20110091418A1 (en) 2006-09-25 2011-04-21 Pathlogica, LLC Methods for treating viral infections using polyamine analogs
JP4929505B2 (ja) 2006-10-31 2012-05-09 Ｉｄｅｃ株式会社 リレーソケット
EP2121586B1 (en) 2007-03-09 2017-03-08 Pathologica LLC Mgbg for the regulation of osteopontin and the treatment of multiple sclerosis
EP2164698A1 (en) 2007-03-09 2010-03-24 Sustainable Solutions, Inc. Regenerated cotton board material and method of manufacture
WO2008112251A1 (en) 2007-03-14 2008-09-18 Progen Pharmaceuticals, Inc. Cyclopropyl-containing polyamine analogs as disease therapies
WO2009018368A1 (en) 2007-07-30 2009-02-05 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Combination treatment of nmda (n-methyl-d-aspartate)-enhancer, glycine transporter inhibitor, d-amino acid oxidase inhibitor (daaoi) for neuropsychiatric disorders
WO2010037395A2 (en) 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
CN102281870B (zh) 2008-12-10 2015-03-04 安徽中人科技有限责任公司 新型控释组合物
US20100189788A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline base formulation
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
EP2283830A1 (en) 2009-07-23 2011-02-16 Actogenix N.V. Aqueous enteric capsule coating
TWI590821B (zh) 2011-01-18 2017-07-11 輝瑞有限公司 固體分子分散液
NO2665471T3 (enExample) 2011-01-19 2018-05-26
DK2675893T3 (en) * 2011-02-18 2019-04-15 Scripps Research Inst Directed differentiation of oligodendrocyte precursor cells into a myelinating cell fate
BR112015016189A8 (pt) 2013-01-08 2019-10-22 Pathologica Llc usos de metilglioxal bis (guanilhidrazona) (“mgbg”), uso de metilglioxal bis (guanilhidrazona) (“mgbg”) e um agente e composição farmacêutica

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010045265A1 (en) * 2008-10-13 2010-04-22 Biovista, Inc. Compositions and methods for treating multiple sclerosis
CN102686222A (zh) * 2009-07-16 2012-09-19 帕萨罗杰卡有限公司 包含mgbg的口服递送药物以及治疗疾病的方法
CN102770142A (zh) * 2010-01-04 2012-11-07 神经科技制药有限公司 二氮嗪在治疗或预防中枢神经系统自体免疫脱髓鞘疾病中的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DANIEL PELLETIER和DAVID A. HAFLER: "Fingolimod for Multiple Sclerosis", 《THE NEW ENGLAND JOURNAL OF MEDICINE》 *
陈艳成编著: "《实用内科诊疗手册》", 31 May 2012, 金盾出版社 *

Also Published As

Publication number Publication date
BR112015016189A2 (pt) 2017-07-11
WO2014110154A1 (en) 2014-07-17
DK2943189T3 (da) 2021-04-06
HK1217451A1 (en) 2017-01-13
IL239851B (en) 2020-07-30
US20150359761A1 (en) 2015-12-17
CN105163730A (zh) 2015-12-16
JP6370804B2 (ja) 2018-08-08
JP2016504389A (ja) 2016-02-12
EP2943189A4 (en) 2016-07-06
BR112015016189A8 (pt) 2019-10-22
CN105163730B (zh) 2018-10-30
US10085955B2 (en) 2018-10-02
CA2896977A1 (en) 2014-07-17
AU2014205529A1 (en) 2015-07-09
JP2018172427A (ja) 2018-11-08
ES2859553T3 (es) 2021-10-04
US20180360783A1 (en) 2018-12-20
NZ749754A (en) 2020-09-25
CA2896977C (en) 2021-12-07
AU2018247351A1 (en) 2018-11-08
NZ709157A (en) 2020-09-25
US10350178B2 (en) 2019-07-16
AU2014205529B2 (en) 2018-08-09
IL239851A0 (en) 2015-08-31
EP2943189A1 (en) 2015-11-18
AU2018247351B2 (en) 2020-04-09
EP3831372A1 (en) 2021-06-09
EP2943189B1 (en) 2021-03-10

Similar Documents

Publication Publication Date Title
CN105163730B (zh) 用于治疗脱髓鞘疾病的方法和组合物
JP6883930B2 (ja) Ｍｇｂｇを含む経口送達用の医薬品および疾患を処置する方法
HK1262206A1 (en) Use of mgbg for manufacturing a medicament for the treatment or prevention of progressive ms and its progression
HK40055723A (en) Mitoguazone for preventing the relapse or the progression of multiple sclerosis
HK40007774A (en) Composition for oral delivery comprising mgbg for use in treating multiple sclerosis
NZ709157B2 (en) Methods and comp0stions for treatment of demyelinating diseases
HK1176548B (en) Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
NZ749754B2 (en) Methods and compositions for treatment of demyelinating diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1262206

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20190308